Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin
Abstract
In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week. All strains displayed an in vitro sensitivity to the drug. Complete clinical resolution was obtained in 8 patients and long-term eradication in 3. No adverse reactions and only minor and reversible laboratory changes were recorded. Ciprofloxacin could be a valuable oral drug in the treatment of severe urinary infections. However, more clinical studies on the development of resistance under therapy and with other dose schedules are indicated.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.